SCHEMBL26631738

SCHEMBL26631738

COC(=O)c1cc(Oc2ccc(F)cc2O)c(Br)cc1[N+](=O)[O-]

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.43
▸ TDP1 Q9NUW8 2/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ HTT P42858 1/20 0.43
▸ MEN1 O00255 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ HSPB1 P04792 2/20 0.39
▸ KCNMA1 Q12791 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.38
▸ SIRT6 Q8N6T7 1/20 0.38
▸ ABCB1 P08183 1/20 0.37
▸ ABCC1 P33527 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ TTR P02766 1/20 0.37
▸ HPGD P15428 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15770914 0.90 HSPB1 (0.51) MAPTTDP1L3MBTL1GAAHTT
SCHEMBL26631827 0.89 MAPT (0.46) MAPTTDP1L3MBTL1GAAHTT
SCHEMBL15067957 0.86 HSPB1 (0.47) MAPTTDP1L3MBTL1GAAHTT
SCHEMBL26631729 0.82 ALDH1A1 (0.46) MAPTTDP1L3MBTL1HTTMEN1
SCHEMBL29634822 0.80 HPGD (0.52) MAPTTDP1L3MBTL1MEN1POLB
SCHEMBL26631818 0.79 TTR (0.48) MAPTTDP1L3MBTL1GAAHTT
SCHEMBL15972175 0.78 POLB (0.51) MAPTTDP1L3MBTL1HTTMEN1
SCHEMBL29634821 0.77 SMN1; SMN2 (0.45) MAPTTDP1GAAHTTMEN1
SCHEMBL15067230 0.77 HSPB1 (0.54) MAPTTDP1L3MBTL1GAAHTT
SCHEMBL2609104 0.76 TDP1 (0.45) MAPTTDP1GAAMEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240092744-A1 TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF THE NATIONAL INSTITUTES OF PHARMACEUTICAL R&D CO., LTD (CN) 2024-03-21 — — US disclosed
CN-114981275-B Tricyclic compound, preparation method and medical application thereof 中国医药研究开发中心有限公司 2023-12-19 — — CN disclosed
EP-4273150-A1 TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF The National Institutes of Pharmaceutical R&D Co., Ltd (CN) 2023-11-08 — — EP disclosed
CN-114981275-A Tricyclic compound, preparation method and medical application thereof 中国医药研究开发中心有限公司 2022-08-30 — — CN disclosed
WO-2022143489-A1 TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 中国医药研究开发中心有限公司 2022-07-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240092744-A1 TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF GOT2, HADH, CYP4A11 MAPT 2211/4885TDP1 1638/4885L3MBTL1 1801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback